Drugs / BIVV003
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03653247 | Mar 2019 → Jul 2025 | sickle cell disease | Sangamo Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIVV003 | “BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.” NCT03653247 ↗ |
| Modality | Cell therapy | “BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with...” NCT03653247 ↗ |
| Route | Intravenous | “BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.” NCT03653247 ↗ |
| Target | BCL11A | “BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with...” NCT03653247 ↗ |